Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2021 16:01 ET | Source: Clene Inc.

Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
August 05, 2021 07:00 ET | Source: Clene Inc.

Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson’s Disease and Multiple Sclerosis

Achieved a statistically significant increase in the Phase 2 program’s primary endpoint (mean change in brain NAD+/NADH ratio) CNM-Au8®, a gold nanocrystal suspension, significantly improved...
August 03, 2021 07:00 ET | Source: Clene Inc.

Clene to Present at Canaccord Genuity's Annual Growth Conference

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
June 30, 2021 07:00 ET | Source: Clene Inc.

Clene to Host Expert Perspectives Webinar on Cellular Energetic Failure and the Unmet Medical Needs in ALS and MS

SALT LAKE CITY, June 30, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
June 28, 2021 07:00 ET | Source: Clene Inc.

Clene Added to Membership of Russell 2000® Index

SALT LAKE CITY, June 28, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
June 15, 2021 07:00 ET | Source: Clene Inc.

Clene to Present at the Raymond James Human Health Innovation Conference

SALT LAKE CITY, June 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
May 24, 2021 08:00 ET | Source: Clene Inc.

Clene Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placement

SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
May 19, 2021 09:00 ET | Source: Clene Inc.

Clene Appoints David J. Matlin as Chairman of the Board

SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
May 17, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with Aging

International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease Clene anticipates the...
May 12, 2021 09:00 ET | Source: Clene Inc.

Clene Nanomedicine Presents Updated Blinded Efficacy Data from Ongoing Phase 2 RESCUE-ALS Study at the ENCALS 2021 Annual Meeting

Preliminary blinded efficacy data suggest CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis (ALS) patients Patients demonstrated improvement from baseline, as compared...